Patent US2854014A successfully refreshed from Google Patents.
Patent EP0156772A2 successfully refreshed from Google Patents.
EP0156772A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Novel pharmaceutical use for CGRPs
Assignee: Sandoz AG
•
Filing: 1985-03-22
•
Granted: —
•
Expires: 2005-03-22
Abstract
Abstract CGRPs. for example human and rat CGRP, and related peptides are effective as regulators of body Ca balance and are useful e,g, for the treatment of Paget's disease, osteoporosis and other related conditions. For this purpose they may be administered alone or in conjunction with a calcitonin, for example human or salmon calcitonin.
Inventors
- 👤 Moise Azria
- 👤 Iain Macintyre
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-30 20:04
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/225; A61K38/23; A61P; A61P3/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
57 words
A method for the regulation of calcium balance, e.g. for the treatment of disease associated with or having an aetiology comprising body calcium imbalance, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a peptide comprising the peptide sequence of a CGRP or of an analogue thereof.
Claim 2
Independent Claim
57 words
A method for the regulation of calcium balance, e.g. for the treatment of disease associated with or having an aetiology comprising body calcium imbalance, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a peptide comprising the peptide sequence of a CGRP or of an analogue thereof.
Claim 3
Dependent Claim
38 words
The use of a peptide comprising the peptide sequence of a CGRP or of an analogue thereof, for the regulation of calcium, e.g. for the treatment of disease associated with or having an aetiology comprising body calcium imbalance.
Claim 4
Dependent Claim
38 words
The use of a peptide comprising the peptide sequence of a CGRP or of an analogue thereof, for the regulation of calcium, e.g. for the treatment of disease associated with or having an aetiology comprising body calcium imbalance.
Claim 5
Dependent Claim
46 words
The use of a peptide comprising the peptide sequence of a CGRP or of an analogue thereof, for the manufacture of a composition for use in the regulation of calcium, e.g. for the treatment of disease associated with or having an aetiology comprising body calcium imbalance.
Claim 6
Dependent Claim
46 words
The use of a peptide comprising the peptide sequence of a CGRP or of an analogue thereof, for the manufacture of a composition for use in the regulation of calcium, e.g. for the treatment of disease associated with or having an aetiology comprising body calcium imbalance.
Claim 7
Dependent Claim
47 words
A method or use according to claim 1 or 2 for: or use according to claim 3 for the manufacture of a composition for use in: the treatment of hypercalaemia, Paget's disease, osteoporosis, bone pain associated with osteoporosis or osteolysis, or pain consequential to metastatic bone deposits.
Claim 8
Independent Claim
19 words
A method or use according to any one of claims 1 to 4 wherein the peptide is rat CGRP.
Claim 9
Independent Claim
19 words
A method or use according to any one of claims 1 to 4 wherein the peptide is human CGRP.
Claim 10
Independent Claim
24 words
A method or use according to any one of claims 1 to 6 wherein the peptide is administered conjointly or concomitantly with a calcitonin.
Claim 11
Dependent Claim
16 words
A method or use according to claim 7 wherein the calcitonin is salmon or human calcitonin.
Claim 12
Dependent Claim
33 words
A pharmaceutical composition comprising a) a peptide comprising the peptide sequence of a CGRP, or an analogue thereof, and b) a calcitonin, together with one or more pharmaceutically acceptable diluents or carriers therefor.
Claim 13
Dependent Claim
33 words
A pharmaceutical composition comprising a) a peptide comprising the peptide sequence of a CGRP, or an analogue thereof, and b) a calcitonin, together with one or more pharmaceutically acceptable diluents or carriers therefor.
Claim 14
Dependent Claim
9 words
A composition according to claim 9 for nasal administration.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.